{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:42:18Z","timestamp":1790649738600,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":1987,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL128525"],"award-info":[{"award-number":["HL128525"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Korea Healthcare Technology R&D Project"},{"name":"Ministry for Health, Welfare and Family Affairs, Republic of Korea","award":["A080588-23"],"award-info":[{"award-number":["A080588-23"]}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009950","name":"Ministry of Education","doi-asserted-by":"publisher","award":["NRF-2016R1D1A1B03934950"],"award-info":[{"award-number":["NRF-2016R1D1A1B03934950"]}],"id":[{"id":"10.13039\/100009950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1111\/jth.13683","type":"journal-article","created":{"date-parts":[[2017,3,25]],"date-time":"2017-03-25T04:05:33Z","timestamp":1490414733000},"page":"1095-1102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Selective effects of oral antiangiogenic tyrosine kinase inhibitors on an animal model of hereditary hemorrhagic telangiectasia"],"prefix":"10.1016","volume":"15","author":[{"given":"Y.H.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.\u2010J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.\u2010W.","family":"Choe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Sprecher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"P. Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.13683_bb0010","first-page":"3","article-title":"Epidemiological investigation of Rendu\u2010Osler disease in France: its geographical distribution and prevalence","volume":"44","author":"Bideau","year":"1989","journal-title":"Popul"},{"key":"10.1111\/jth.13683_bb0015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1046\/j.1365-2796.1999.00398.x","article-title":"Hereditary haemorrhagic telangiectasia: a population\u2010based study of prevalence and mortality in Danish patients","volume":"245","author":"Kjeldsen","year":"1999","journal-title":"J Intern Med"},{"key":"10.1111\/jth.13683_bb0020","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/jmg.2005.030833","article-title":"Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease","volume":"43","author":"Abdalla","year":"2006","journal-title":"J Med Genet"},{"key":"10.1111\/jth.13683_bb0025","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.blre.2010.07.001","article-title":"Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment","volume":"24","author":"Shovlin","year":"2010","journal-title":"Blood Rev"},{"key":"10.1111\/jth.13683_bb0030","first-page":"3487","article-title":"Real\u2010time imaging of de novo arteriovenous malformation in a mouse model of hereditary hemorrhagic telangiectasia","volume":"119","author":"Park","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1111\/jth.13683_bb0035","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1161\/ATVBAHA.114.303984","article-title":"Common and distinctive pathogenetic features of arteriovenous malformations in hereditary hemorrhagic telangiectasia 1 and hereditary hemorrhagic telangiectasia 2 animal models\u2013brief report","volume":"34","author":"Garrido\u2010Martin","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1111\/jth.13683_bb0040","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s10456-014-9436-3","article-title":"VEGF neutralization can prevent and normalize arteriovenous malformations in an animal model for hereditary hemorrhagic telangiectasia 2","volume":"17","author":"Han","year":"2014","journal-title":"Angiogenesis"},{"key":"10.1111\/jth.13683_bb0045","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/ana.22348","article-title":"Arteriovenous malformation in the adult mouse brain resembling the human disease","volume":"69","author":"Walker","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1111\/jth.13683_bb0050","first-page":"591","article-title":"Plasma level and tissue expression of angiogenic factors in patients with hereditary hemorrhagic telangiectasia","volume":"15","author":"Sadick","year":"2005","journal-title":"Int J Mol Med"},{"key":"10.1111\/jth.13683_bb0055","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000072411","article-title":"Vascular endothelial growth factor serum levels are elevated in patients with hereditary hemorrhagic telangiectasia","volume":"110","author":"Cirulli","year":"2003","journal-title":"Acta Haematol"},{"key":"10.1111\/jth.13683_bb0060","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00277-006-0147-8","article-title":"Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab","volume":"85","author":"Flieger","year":"2006","journal-title":"Ann Hematol"},{"key":"10.1111\/jth.13683_bb0065","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/lary.20757","article-title":"Hereditary hemorrhagic telangiectasia\/avastin","volume":"120","author":"Davidson","year":"2010","journal-title":"Laryngoscope"},{"key":"10.1111\/jth.13683_bb0070","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/lt.21417","article-title":"Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia","volume":"14","author":"Mitchell","year":"2008","journal-title":"Liver Transpl"},{"key":"10.1111\/jth.13683_bb0075","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMc091271","article-title":"More on bevacizumab in hereditary hemorrhagic telangiectasia","volume":"361","author":"Oosting","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.13683_bb0080","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jama.2016.11724","article-title":"Effect of topical intranasal therapy on epistaxis frequency in patients with hereditary hemorrhagic telangiectasia: a randomized clinical trial","volume":"316","author":"Whitehead","year":"2016","journal-title":"JAMA"},{"key":"10.1111\/jth.13683_bb0085","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/jama.2016.11387","article-title":"Effect of bevacizumab nasal spray on epistaxis duration in hereditary hemorrhagic telangectasia: a randomized clinical trial","volume":"316","author":"Dupuis\u2010Girod","year":"2016","journal-title":"JAMA"},{"key":"10.1111\/jth.13683_bb0090","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/nrd2380","article-title":"Molecular basis for sunitinib efficacy and future clinical development","volume":"6","author":"Faivre","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1111\/jth.13683_bb0095","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0092-8674(04)00215-6","article-title":"Mechanism of activation of the RAF\u2010ERK signaling pathway by oncogenic mutations of B\u2010RAF","volume":"116","author":"Wan","year":"2004","journal-title":"Cell"},{"key":"10.1111\/jth.13683_bb0100","first-page":"443","article-title":"Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma","volume":"71","author":"Keisner","year":"2011","journal-title":"Drugs"},{"key":"10.1111\/jth.13683_bb0105","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nrc2559","article-title":"Targeting cancer with small molecule kinase inhibitors","volume":"9","author":"Zhang","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1111\/jth.13683_bb0110","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.clinthera.2007.07.022","article-title":"Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors","volume":"29","author":"Adams","year":"2007","journal-title":"Clin Ther"},{"key":"10.1111\/jth.13683_bb0115","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.1158\/1078-0432.CCR-06-1249","article-title":"Sorafenib for the treatment of advanced renal cell carcinoma","volume":"12","author":"Kane","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1111\/jth.13683_bb0120","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1182\/blood-2007-08-107359","article-title":"ALK5\u2010 and TGFBR2\u2010independent role of ALK1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2","volume":"111","author":"Park","year":"2008","journal-title":"Blood"},{"key":"10.1111\/jth.13683_bb0125","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.taap.2014.04.015","article-title":"Erlotinib promotes endoplasmic reticulum stress\u2010mediated injury in the intestinal epithelium","volume":"278","author":"Fan","year":"2014","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1111\/jth.13683_bb0130","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1158\/1078-0432.CCR-09-2904","article-title":"Depletion of tumor\u2010associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects","volume":"16","author":"Zhang","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1111\/jth.13683_bb0135","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00280-005-0079-3","article-title":"Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models","volume":"57","author":"Ouchi","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1111\/jth.13683_bb0140","doi-asserted-by":"crossref","first-page":"44004","DOI":"10.1117\/1.2003369","article-title":"Hyperspectral imaging of hemoglobin saturation in tumor microvasculature and tumor hypoxia development","volume":"10","author":"Sorg","year":"2005","journal-title":"J Biomed Opt"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.13683","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622042702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622042702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jth.13683\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:16:41Z","timestamp":1761535001000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622042702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S1538783622042702"],"URL":"https:\/\/doi.org\/10.1111\/jth.13683","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selective effects of oral antiangiogenic tyrosine kinase inhibitors on an animal model of hereditary hemorrhagic telangiectasia","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.13683","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2017 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}